Beneficial Effects of Paraffin Bath Therapy as Additional Treatment of Chronic Hand Eczema: A Randomized, Single-Blind, Active-Controlled, Parallel-Group Study

被引:3
|
作者
Waked, Intsar S. [2 ]
Ibrahim, Zizi M. [1 ,2 ]
机构
[1] Princess Nourah Bint Abdulrahman Univ, Rehabil Sci Dept, Coll Hlth & Rehabil Sci, Riyadh 11671, Saudi Arabia
[2] Cairo Univ, Fac Phys Therapy, Dept Phys Therapy Surg, Giza, Egypt
关键词
paraffin bath therapy; hand eczema; SCORing Atopic Dermatitis (SCORAD); dermatology life quality index; itching; QUALITY-OF-LIFE; ATOPIC-DERMATITIS; MOBILIZATION TECHNIQUES; SCORAD INDEX; WAX BATHS; FOLLOW-UP; POPULATION; SEVERITY; VALIDATION; GUIDELINES;
D O I
10.1089/acm.2020.0356
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Objective: Chronic hand eczema (CHE) is a common inflammatory skin disease with a major psychological and socioeconomic impacts on patients' quality of life (QoL) and work ability. To the best of knowledge, this study is the first randomized-controlled trial conducted to evaluate the effect of paraffin bath therapy in management of hand eczema and its related symptoms. Design: This study was a parallel-group, active-control, randomized clinical trial with measures at pretreatment, 6th week, and 12th week of treatment. Settings: The study took place at the Outpatient Clinic of Faculty of Physical Therapy, Cairo University, and some licensed rehabilitation centers in Cairo for a 1-year period. Subjects: Sixty patients with moderate to severe CHE were randomly assigned into two groups of equal number; the paraffin bath therapy group and the control group. Interventions: The paraffin group received paraffin bath therapy for 5 days a week for 12 weeks, in addition to the routine skin care program, while the control group only received the routine skin care program. Outcome measures: SCORing Atopic Dermatitis (SCORAD) was used to assess the severity of atopic dermatitis and dermatology life quality index (DLQI) to assess the effect of CHE on quality of patients' life. All measurements were obtained before, at the 6th week, and at the 12th week of treatment. Results: Marked improvement in the severity of the disease symptoms was observed, reflected by a highly decrease in objective SCORAD score in the paraffin group over time more than the control group. The percentage of reduction was 28.6% in paraffin group versus 0.41% in control group. Subjective item score (itching and sleepiness) was reduced in the paraffin group more than the control group with a percentage of improvement (47% and 5.5%), respectively. Regarding QoL measure, there were highly positive changes in DLQI in paraffin group more than the control group. The percentage of improvement was 60% in paraffin group and 3.8% in control group. Conclusions: Paraffin bath therapy applied for a 12-week duration seems to be effective, both in reducing severity of eczema symptoms and improving QoL in patients with CHE.
引用
收藏
页码:1144 / 1150
页数:7
相关论文
共 50 条
  • [41] Automated psychological therapy using virtual reality (VR) for patients with persecutory delusions: study protocol for a single-blind parallel-group randomised controlled trial (THRIVE)
    Freeman, Daniel
    Lister, Rachel
    Waite, Felicity
    Yu, Ly-Mee
    Slater, Mel
    Dunn, Graham
    Clark, David
    TRIALS, 2019, 20 (1)
  • [42] Automated psychological therapy using virtual reality (VR) for patients with persecutory delusions: study protocol for a single-blind parallel-group randomised controlled trial (THRIVE)
    Daniel Freeman
    Rachel Lister
    Felicity Waite
    Ly-Mee Yu
    Mel Slater
    Graham Dunn
    David Clark
    Trials, 20
  • [43] Safety and Tolerability of Ponesimod Compared to Teriflunomide in Patients with Relapsing Multiple Sclerosis: Results of the Randomized, Active-Controlled, Double-Blind, Parallel-Group Phase 3 OPTIMUM Study
    Sprenger, Till
    Burcklen, Michel
    Freedman, Mark S.
    Fox, Robert
    Havrdova, Eva K.
    Hennessy, Brian
    Hohlfeld, Reinhard
    Lublin, Fred
    Montalban, Xavier
    Pozzilli, Carlo
    Vaclavkova, Andrea
    Scherz, Tatiana
    Linscheid, Philippe
    Pirozek-Lawniczek, Magdalena
    Kracker, Hilke
    Kappos, Ludwig
    NEUROLOGY, 2020, 94 (15)
  • [44] Efficacy and safety of ponesimod compared to teriflunomide in patients with relapsing multiple sclerosis: results of the randomized, active-controlled, double-blind, parallel-group phase 3 OPTIMUM study
    Kappos, L.
    Burcklen, M.
    Freedman, M. S.
    Fox, R.
    Havrdova, E. K.
    Hennessy, B.
    Hohlfeld, R.
    Lublin, F.
    Montalban, X.
    Pozzilli, C.
    Scherz, T.
    Linscheid, P.
    Pirozek-Lawniczek, M.
    Kracker, H.
    Sprenger, T.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 30 - 31
  • [45] Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a 3-adrenoceptor agonist, in patients with overactive bladder in Asia
    Kuo, Hann-Chorng
    Lee, Kyu-Sung
    Na, Yanqun
    Sood, Rajeev
    Nakaji, Shigeru
    Kubota, Yosuke
    Kuroishi, Kentarou
    NEUROUROLOGY AND URODYNAMICS, 2015, 34 (07) : 685 - 692
  • [46] Whole body and local cryotherapy in restless legs syndrome: A randomized, single-blind, controlled parallel group pilot study
    Happe, Svenja
    Evers, Stefan
    Thiedemann, Christian
    Bunten, Sabine
    Siegert, Rudolf
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2016, 370 : 7 - 12
  • [47] A randomized, single-blind, parallel-group comparative study on the effects of long-term pineapple intake for improvement of skin function and intestinal environment in healthy subjects
    Oyal, Hiroko
    Masuda, Takamasa
    Ishikawa, Hirohito
    Takimoto, Yosuke
    Seki, Shihoko
    Hotta, Takuya
    Otaki, Hiromi
    Araki, Yusuke
    Koyanagi, Eriko
    Shinoharas, Hiroe
    Nakanos, Masahiro
    Osawa, Toshihiko
    JOURNAL OF THE JAPANESE SOCIETY FOR FOOD SCIENCE AND TECHNOLOGY-NIPPON SHOKUHIN KAGAKU KOGAKU KAISHI, 2023, 70 (02): : 73 - 83
  • [48] Combination oxycodone 5 mg/Ibuprofen 400 mg for the treatment of pain after abdominal or pelvic surgery in women: A randomized, double-blind, placebo- and active-controlled parallel-group study
    Singla, N
    Pong, AP
    Newman, K
    CLINICAL THERAPEUTICS, 2005, 27 (01) : 45 - 57
  • [49] Efficacy and Safety of Pemafibrate Extended-Release Tablet: a Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group Comparison Trial
    Arai, Hidenori
    Yamashita, Shizuya
    Araki, Eiichi
    Yokote, Koutaro
    Tanigawa, Ryohei
    Saito, Ayumi
    Yamasaki, Sayumi
    Suganami, Hideki
    Ishibashi, Shun
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2024,
  • [50] Protocol for a randomised, single-blind, two-arm, parallel-group controlled trial of the efficacy of rhinothermy delivered by nasal high flow therapy in the treatment of the common cold
    Bird, Grace
    Braithwaite, Irene
    Harper, James
    McKinstry, Steven
    Koorevaar, Iris
    Fingleton, James
    Semprini, Alex
    Dilcher, Meik
    Jennings, Lance
    Weatherall, Mark
    Beasley, Richard
    BMJ OPEN, 2019, 9 (06):